All In Biotech

Drug Trial Radar · NCT06163430

A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Mar 26, 2024

Primary completion

Nov 30, 2029

Study completion May 31, 2030

Sponsor

Sponsor type
Industry
First posted
Dec 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (Tern-701) can treat this type of blood cancer. The goal of this study is to learn about the safety of different doses (amounts) of MK-4208 (Tern-701) and if people tolerate them. Researchers also want to find the highest dose of MK-4208 (Tern-701) that people can tolerate and may work to treat blood cancer.

Conditions

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Chronic Myeloid Leukemia, Chronic Phase
  • Chronic Myeloid Leukemia

Interventions

  • MK-4208Drug

    40 mg and 100 mg oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence of Dose Limiting Toxicities (DLTs) During the First Cycle of InterventionTime frame: Up to 28 days
  2. Parts 1, 2m and 3: Number of Participants with at Least One AETime frame: Up to 3 years
  3. Parts 1, 2m and 3: Number of Participants with at Least One Serious Adverse Event (SAE)Time frame: Up to 3 years
  4. Parts 1, 2m and 3: Number of Participants who Discontinued Study Intervention Due to an AETime frame: Up to 3 years
  5. Parts 2, 2m and 3: Number of Participants with a Complete Hematologic Response (CHR)Time frame: Baseline and up to 3 years
  6. Parts 2, 2m and 3: Number of Participants with a Molecular response (MR)Time frame: Baseline and up to 3 years
  7. Parts 2, 2m and 3: Number of Participants who had Best Categorical Shift in BCR-ABL1 Transcript Levels From BaselineTime frame: Baseline and up to 3 years

Locations

54 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Alabama Medicine (UAB Medicine)

    Birmingham, Alabama · Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • UC Irvine Health

    Orange, California · Recruiting

  • Rocky Mountain Cancer Centers, LLP

    Lone Tree, Colorado · Recruiting

  • Florida Cancer Specialists - South Region Research Office

    Fort Myers, Florida · Not yet recruiting

  • Florida Cancer Affiliates - Ocala

    Ocala, Florida · Recruiting

  • Florida Cancer Specialists - North Region Research Office

    St. Petersburg, Florida · Not yet recruiting

  • Florida Cancer Specialists - East Region Research Office

    West Palm Beach, Florida · Not yet recruiting

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia · Recruiting

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York · Recruiting

  • Atrium Health Levine Cancer Institute

    Winston-Salem, North Carolina · Recruiting

  • Willamette Valley Cancer Institute and Research Center

    Eugene, Oregon · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Thomas Jefferson University - Center City (Philadelphia)

    Philadelphia, Pennsylvania · Recruiting

  • Tristar BMT

    Nashville, Tennessee · Recruiting

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Monash Medical Centre

    Clayton, Victoria, Australia · Not yet recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Not yet recruiting

  • Royal Perth Hospital

    Perth, Western Australia, Australia · Recruiting

  • Institut Bergonié

    Bordeaux, France · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Recruiting

  • CHU de Nantes (University Hospital of Nantes) - Hôtel Dieu

    Nantes, France · Recruiting

  • Hôpital Saint Louis

    Paris, France · Recruiting

  • Centre Hospitalier Lyon-Sud

    Pierre-Bénite, France · Recruiting

  • Centre Léon Bérard

    Lyon, Auvergne-Rhône-Alpes, France · Recruiting

  • Universitätsklinikum Aachen

    Aachen, Germany · Recruiting

  • Charité Campus Virchow-Klinikum - Universitätsmedizin Berlin

    Berlin, Germany · Recruiting

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Germany · Recruiting

  • Medizinische Hochschule Hannover

    Hanover, Germany · Recruiting

  • Universitätsklinikum Jena

    Jena, Germany · Recruiting

  • Universitätsklinikum Mannheim

    Mannheim, Germany · Recruiting

  • Klinikum rechts der lsar der Technischen Universität München

    München, Germany · Recruiting

  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola

    Bologna, Italy · Recruiting

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy · Recruiting

  • Fondazione IRCCS San Gerardo dei Tintori - SC Centro di Ricerca Fase I

    Monza, Italy · Recruiting

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Italy · Recruiting

  • Auckland City Hospital

    Auckland, New Zealand · Not yet recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.